argenx: Upgrading To Buy, The VYVGART Growth Cycle Has Further To Go

Impact · against what's priced in

Argenx receives a positive catalyst from an analyst upgrade to BUY, driven by the continued commercial scaling of VYVGART and under-appreciated pipeline potential. The shift in rating and the specific $1,050 price target provide immediate institutional momentum.

ARGX+0.60

No priced-in read yet

In context

The upgrade to BUY and a $1,050 price target, combined with the view that pipeline assets like empasiprubart are not fully reflected in the valuation, suggests the stock is currently undervalued relative to its growth trajectory.

Read from the article alone

• pharmaceuticals
• biotech
• ARGX
• autoimmune
• growth stock
• pipeline
• price target

Search tags